710 related articles for article (PubMed ID: 30446589)
1. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
Choi BD; Maus MV; June CH; Sampson JH
Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
[TBL] [Abstract][Full Text] [Related]
2. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
Front Immunol; 2020; 11():594271. PubMed ID: 33224149
[TBL] [Abstract][Full Text] [Related]
4. CAR T cells for brain tumors: Lessons learned and road ahead.
Akhavan D; Alizadeh D; Wang D; Weist MR; Shepphird JK; Brown CE
Immunol Rev; 2019 Jul; 290(1):60-84. PubMed ID: 31355493
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.
Feldman L; Brown C; Badie B
Neurosurgery; 2021 May; 88(6):1056-1064. PubMed ID: 33575786
[TBL] [Abstract][Full Text] [Related]
6. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
7. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
[No Abstract] [Full Text] [Related]
8. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
Zhou S; Sun H; Choi SI; Yin J
Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
[TBL] [Abstract][Full Text] [Related]
9. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma.
Huang J; Zheng M; Zhang Z; Tang X; Chen Y; Peng A; Peng X; Tong A; Zhou L
Cancer Immunol Immunother; 2021 Sep; 70(9):2453-2465. PubMed ID: 33543339
[TBL] [Abstract][Full Text] [Related]
11. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
Feldman L; Brown C; Badie B
Neuromolecular Med; 2022 Mar; 24(1):35-40. PubMed ID: 34665390
[TBL] [Abstract][Full Text] [Related]
13. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
Choi BD; Curry WT; Carter BS; Maus MV
Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
[TBL] [Abstract][Full Text] [Related]
15. Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.
Kang CH; Kim Y; Lee SM; Choi SU; Park CH
Anticancer Res; 2021 Apr; 41(4):1811-1819. PubMed ID: 33813386
[TBL] [Abstract][Full Text] [Related]
16. CAR T-Cell Therapies in Glioblastoma: A First Look.
Migliorini D; Dietrich PY; Stupp R; Linette GP; Posey AD; June CH
Clin Cancer Res; 2018 Feb; 24(3):535-540. PubMed ID: 29158268
[TBL] [Abstract][Full Text] [Related]
17. Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma.
Samaha H; El Naggar S; Ahmed N
Immunotherapy; 2015; 7(5):481-5. PubMed ID: 26065474
[No Abstract] [Full Text] [Related]
18. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
Ren PP; Li M; Li TF; Han SY
Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
[TBL] [Abstract][Full Text] [Related]
19. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
[TBL] [Abstract][Full Text] [Related]
20. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
